ONO Pharmaceutical Co(OPHLF)
$15.40-0.00 (-0.03%)
OPHLF
ONO Pharmaceutical Co financials statements
$15.40
At close:-0.00 (-0.03%)
ONO Pharmaceutical Co (OPHLF) Income Statement
21 Followers
ONO Pharmaceutical Co Income Statement
Last quarter (Q3 2026), ONO Pharmaceutical Co's total revenue was ¥139.90B, an increase of 20.44% from the same quarter last year. In Q3, ONO Pharmaceutical Co's net income was ¥28.86B. See ONO Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| ¥ 486.87B | ¥ 515.78B | ¥ 502.67B | ¥ 447.19B | ¥ 361.36B | |
| ¥ 335.47B | ¥ 374.07B | ¥ 372.67B | ¥ 334.28B | ¥ 264.91B | |
| ¥ 272.08B | ¥ 270.73B | ¥ 209.10B | ¥ 181.99B | ¥ 150.00B | |
| Depreciation and Amortization | ¥ 26.89B | ¥ 37.75B | ¥ 18.14B | ¥ 17.45B | ¥ 17.72B |
| ¥ 87.86B | ¥ 133.94B | ¥ 181.98B | ¥ 161.11B | ¥ 122.82B | |
| ¥ 63.38B | ¥ 103.33B | ¥ 163.56B | ¥ 152.29B | ¥ 114.91B | |
| ¥ -4.06B | ¥ -10.68B | ¥ 173.00M | ¥ -8.76B | ¥ -9.89B | |
| ¥ 59.33B | ¥ 92.65B | ¥ 163.73B | ¥ 143.53B | ¥ 105.03B | |
| ¥ 50.05B | ¥ 69.77B | ¥ 127.98B | ¥ 112.72B | ¥ 80.52B | |
| Per Share Metrics | |||||
| Basic EPS | ¥ 106.55 | ¥ 148.49 | ¥ 266.61 | ¥ 230.85 | ¥ 162.19 |
| Diluted EPS | ¥ 106.41 | ¥ 148.42 | ¥ 266.57 | ¥ 230.79 | ¥ 162.16 |
| Weighted Average Shares Outstanding | 469.69M | 469.85M | 480.01M | 488.30M | 496.46M |
| Weighted Average Shares Outstanding (Diluted) | 469.77M | 469.97M | 480.04M | 488.35M | 496.53M |
Currency in JPY
